{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:49:15Z","timestamp":1780580955206,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","award":["H26-nanchitou(nan)-ippan-074"],"award-info":[{"award-number":["H26-nanchitou(nan)-ippan-074"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.nmd.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T03:18:14Z","timestamp":1498101494000},"page":"918-922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Memory B cell resurgence requires repeated rituximab in myasthenia gravis"],"prefix":"10.1016","volume":"27","author":[{"given":"Kohei","family":"Muto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Unai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waka","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Haji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Udaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2017.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.06.012_bib0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/CPJ.0b013e31828d9fec","article-title":"Myasthenia gravis: five new things","volume":"3","author":"Statland","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2017.06.012_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","article-title":"When the patient fails to respond to treatment: myasthenia gravis","volume":"7","author":"Hilton-Jones","year":"2007","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0035","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nmd.2017.06.012_bib0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00002281-200405000-00003","article-title":"B cells as therapeutic targets for rheumatic diseases","volume":"16","author":"Looney","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2017.06.012_bib0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.06.012_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2017.06.012_bib0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2017.06.012_bib0070","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2017.06.012_bib0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2017.06.012_bib0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.nmd.2017.06.012_bib0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2017.06.012_bib0090","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0095","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.4049\/jimmunol.177.6.3728","article-title":"A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation","volume":"177","author":"Fecteau","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0100","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.4049\/jimmunol.178.10.6624","article-title":"A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus","volume":"178","author":"Wei","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2012.00302","article-title":"Advances in human B cell phenotypic profiling","volume":"3","author":"Kaminski","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2017.06.012_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2017.06.012_bib0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2017.06.012_bib0120","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/ar3042","article-title":"Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients","volume":"12","author":"Rodr\u00edguez-Bayona","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2017.06.012_bib0125","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B cell populations revealed by B cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J Immunol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616311476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616311476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:05:53Z","timestamp":1760774753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616311476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0960896616311476"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2017.06.012","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}